Impact of postmenopausal hormone therapy on cardiovascular events and cancer. Paper's main conclusion is no longer justified when data from all trials are considered
Seagroatt, V.
Bmj 315(7109): 677; Author Reply 678-9
1997
ISSN/ISBN: 0959-8138 PMID: 9310577 Document Number: 469707
Document emailed within 1 workday
Related Documents
Shah, S.; Rhodes, L. 1997: Impact of postmenopausal hormone therapy on cardiovascular events and cancer. Search for studies was limited Bmj 315(7109): 676-7; Author Reply 678-9VandeKieft, G. 1996: Postmenopausal hormone therapy and cardiovascular risk Journal of Family Practice 43(5): 437-438
Chae, C.U.; Ridker, P.M.; Manson, J.E. 1997: Postmenopausal hormone replacement therapy and cardiovascular disease Thrombosis and Haemostasis 78(1): 770-780
Middeldorp, S.; Büller, H.R.; Vandenbroucke, J.P.; Helmerhorst, F.M.; Rosendaal, F.R. 2002: Adverse cardiovascular effects of postmenopausal hormone replacement therapy Nederlands Tijdschrift Voor Geneeskunde 146(45): 2123-2127
Zhang, Y. 2002: Further recognize the benefit and risk of postmenopausal hormone replacement therapy on atherosclerotic cardiovascular diseases Zhonghua Fu Chan Ke Za Zhi 37(6): 321-323
Chen, F.P.; Lee, N.; Soong, Y.K.; Huang, K.E. 2001: Short- and long-term effects of hormone replacement therapy on cardiovascular risk factors in postmenopausal women Chang Gung Medical Journal 24(7): 431-439
Boissel, J.P. 1984: Impact of randomized controlled trials on the progress of therapy in cardiovascular diseases Revue d'Epidemiologie et de Sante Publique 32(3-4): 212-218
Chen, F.-P. 2009: Postmenopausal hormone therapy and risk of breast cancer Chang Gung Medical Journal 32(2): 140-147
Arteaga-Gómez, A.C.; Castellanos-Barroso, G.; Colin-Valenzuela, A.; García-Vargas, J.; Márquez-Acosta, G.; Reyes-Muñoz, E. 2011: Hormone therapy effect in postmenopausal women with history of endometrial cancer Ginecologia y Obstetricia de Mexico 79(1): 11-17
Dunn, N. 2001: Cardiovascular events in users of sildenafil. Paper does not provide any reassurance Bmj 323(7303): 50-51
Inafuku, K.; Inari, H.; Goto, N.; Kawamoto, M.; Hatori, S.; Tanabe, H.; Masuda, M. 2014: A case of postmenopausal breast cancer becoming HER2 positive after neoadjuvant hormone therapy Gan to Kagaku Ryoho. Cancer and ChemoTherapy 41(4): 487-489
Vavilis, D.; Zafrakas, M.; Goulis, D.G.; Pantazis, K.; Agorastos, T.; Bontis, J.N. 2009: Hormone therapy for postmenopausal breast cancer survivors: a survey among obstetrician-gynaecologists European Journal of Gynaecological Oncology 30(1): 82-84
Novoa Vargas, A.; Font López, K.C.; Amador, D.D. 2011: Letrozole vs. tamoxifen as neoadjuvant therapy for postmenopausal patients with hormone-dependent locally-advanced breast cancer Ginecologia y Obstetricia de Mexico 79(9): 553-557
Klaassen, D.J.; Rapp, E.F.; Hirte, W.E. 1976: Response to medroxyprogesterone acetate (NSC-26386) as secondary hormone therapy for metastatic breast cancer in postmenopausal women Cancer Treatment Reports 60(3): 251-253
Kessler, C.M.; Legault, C. 1995: Effect of hormone replacement therapy on the activities of factor VII and protein C in postmenopausal women women The postmenopausal estrogen/progestin intervention trial Blood 86(10 Suppl 1): 200A
Lapidus, L.; Lindstedt, G.; Lundberg, P.A.; Bengtsson, C.; Gredmark, T. 1986: Concentrations of sex-hormone binding globulin and corticosteroid binding globulin in serum in relation to cardiovascular risk factors and to 12-year incidence of cardiovascular disease and overall mortality in postmenopausal women Clinical Chemistry 32(1 Part 1): 146-152
Iavelov, I.S. 2006: Aspirin in primary prevention of cardiovascular events in women and men (a meta-analysis of randomized controlled trials) Kardiologiia 46(3): 75-76
Pinkerton, J.V.; Wilson, C.S.; Kaunitz, A.M. 2022: Reassuring data regarding the use of hormone therapy at menopause and risk of breast cancer Menopause 29(9): 1001-1004
Evans, W.K.; Coyle, D.; Gafni, A.; Walker, H. 2003: Which cancer clinical trials should be considered for economic evaluation? Selection criteria from the National Cancer Institute of Canada's Working Group on Economic Analysis Chronic diseases in Canada 24(4): 102-107
2005: Cardiovascular risk to be considered. Proinsulin test for stage-adjusted therapy MMW Fortschritte der Medizin 147(10): 49